Susan Thornton on Unmet Needs in Cutaneous Lymphoma

Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.

Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.

Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.

Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.

Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.

Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.